{"id":76673,"date":"2026-08-26T12:56:59","date_gmt":"2026-08-26T04:56:59","guid":{"rendered":"https:\/\/flcube.com\/?p=76673"},"modified":"2026-08-26T12:57:00","modified_gmt":"2026-08-26T04:57:00","slug":"mhlw-approves-takedas-first-in-class-orzeyful-oveporexton-for-narcolepsy-type-1-in-japan","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76673","title":{"rendered":"MHLW Approves Takeda&#8217;s First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Takeda Pharmaceutical Company Limited (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/4502:TYO\">TYO: 4502<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/TAK:NYSE\">NYSE: TAK<\/a>)<\/strong> announced that the <strong>Japanese Ministry of Health, Labour and Welfare (MHLW)<\/strong> has approved <strong>ORZEYFUL (oveporexton)<\/strong> for the treatment of <strong>narcolepsy type 1 (NT1, narcolepsy with cataplexy)<\/strong> in adults. The <strong>first\u2011in\u2011class oral orexin receptor 2 (OX2R) agonist<\/strong> is the only medicine indicated in Japan to treat the underlying cause of NT1, marking a paradigm shift from symptom management to disease\u2011targeted therapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>MHLW (Japan)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>26 Aug 2026<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ORZEYFUL (oveporexton), oral OX2R agonist<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First\u2011in\u2011class; only medicine in Japan addressing the underlying cause of NT1<\/td><\/tr><tr><td><strong>Supporting Data<\/strong><\/td><td>Global Phase 3 FirstLight (TAK\u2011861\u20113001) and RadiantLight (TAK\u2011861\u20113002) studies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Oveporexton<\/strong> \u2013 first\u2011in\u2011class oral <strong>orexin receptor 2 (OX2R) agonist<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Directly targets the orexin deficiency that drives NT1, replacing missing orexin signalling rather than merely suppressing symptoms<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Only approved therapy in Japan indicated for the underlying cause of NT1, distinguishing it from symptomatic treatments such as wake\u2011promoting agents and anticataplectics<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-firstlight-amp-radiantlight-phase-3\" class=\"wp-block-heading\">Clinical Evidence \u2013 FirstLight &amp; RadiantLight (Phase 3)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>NT1 Symptom Improvement<\/strong><\/td><td>Statistically significant improvements across the full range of symptoms assessed<\/td><\/tr><tr><td><strong>Excessive Daytime Sleepiness<\/strong><\/td><td>Significant improvement<\/td><\/tr><tr><td><strong>Cataplexy<\/strong><\/td><td>Significant improvement<\/td><\/tr><tr><td><strong>Secondary Measures<\/strong><\/td><td>Broad improvements across evaluated endpoints<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Generally well\u2011tolerated; safety profile consistent across clinical studies to date<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The approval is based on a comprehensive clinical programme, including the global Phase 3 <strong>FirstLight (TAK\u2011861\u20113001)<\/strong> and <strong>RadiantLight (TAK\u2011861\u20113002)<\/strong> studies, which demonstrated that <strong>oveporexton<\/strong> offers statistically significant improvements across the full spectrum of NT1 symptoms \u2014 including excessive daytime sleepiness, cataplexy, and other secondary measures \u2014 with a generally well\u2011tolerated and consistent safety profile.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Paradigm Shift:<\/strong> As the first therapy to address the underlying orexin deficiency in NT1, ORZEYFUL resets the standard of care in a chronic, rare neurological disease long dependent on symptomatic treatments.<\/li>\n\n\n\n<li><strong>Rare Disease Economics:<\/strong> NT1&#8217;s chronic nature and clear unmet need support durable uptake potential, with orphan\u2011style pricing and favourable adherence dynamics expected in Japan.<\/li>\n\n\n\n<li><strong>Global Catalyst:<\/strong> The Japanese approval anchors Takeda&#8217;s orexin programme ahead of potential filings in other major markets, where orexin agonists represent one of neuroscience&#8217;s most closely watched new mechanisms.<\/li>\n\n\n\n<li><strong>Portfolio Fit:<\/strong> The launch strengthens <strong>Takeda&#8217;s<\/strong> neuroscience franchise and adds a differentiated, first\u2011in\u2011class asset to its Japan commercial portfolio.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch, regulatory filings in additional markets, and clinical expectations for ORZEYFUL. Actual results may differ due to risks including market adoption, regulatory outcomes in other regions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the Japanese Ministry of Health,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":76677,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11,4908],"tags":[874,15,345,1141],"class_list":["post-76673","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","category-pic","tag-nyse-tak","tag-product-approvals","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MHLW Approves Takeda&#039;s First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. The first\u2011in\u2011class oral orexin receptor 2 (OX2R) agonist is the only medicine indicated in Japan to treat the underlying cause of NT1, marking a paradigm shift from symptom management to disease\u2011targeted therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76673\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MHLW Approves Takeda&#039;s First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan\" \/>\n<meta property=\"og:description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. The first\u2011in\u2011class oral orexin receptor 2 (OX2R) agonist is the only medicine indicated in Japan to treat the underlying cause of NT1, marking a paradigm shift from symptom management to disease\u2011targeted therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76673\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-26T04:56:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-26T04:57:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2606.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76673#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76673\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MHLW Approves Takeda&#8217;s First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan\",\"datePublished\":\"2026-08-26T04:56:59+00:00\",\"dateModified\":\"2026-08-26T04:57:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76673\"},\"wordCount\":451,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76673#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2606.webp\",\"keywords\":[\"NYSE: TAK\",\"Product approvals\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\",\"Drug\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76673#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76673\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76673\",\"name\":\"MHLW Approves Takeda's First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76673#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76673#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2606.webp\",\"datePublished\":\"2026-08-26T04:56:59+00:00\",\"dateModified\":\"2026-08-26T04:57:00+00:00\",\"description\":\"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. The first\u2011in\u2011class oral orexin receptor 2 (OX2R) agonist is the only medicine indicated in Japan to treat the underlying cause of NT1, marking a paradigm shift from symptom management to disease\u2011targeted therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76673#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76673\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76673#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2606.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2606.webp\",\"width\":1080,\"height\":608,\"caption\":\"MHLW Approves Takeda's First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76673#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MHLW Approves Takeda&#8217;s First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MHLW Approves Takeda's First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan - Insight, China&#039;s Pharmaceutical Industry","description":"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. The first\u2011in\u2011class oral orexin receptor 2 (OX2R) agonist is the only medicine indicated in Japan to treat the underlying cause of NT1, marking a paradigm shift from symptom management to disease\u2011targeted therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76673","og_locale":"en_US","og_type":"article","og_title":"MHLW Approves Takeda's First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan","og_description":"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. The first\u2011in\u2011class oral orexin receptor 2 (OX2R) agonist is the only medicine indicated in Japan to treat the underlying cause of NT1, marking a paradigm shift from symptom management to disease\u2011targeted therapy.","og_url":"https:\/\/flcube.com\/?p=76673","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-26T04:56:59+00:00","article_modified_time":"2026-08-26T04:57:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2606.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76673#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76673"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MHLW Approves Takeda&#8217;s First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan","datePublished":"2026-08-26T04:56:59+00:00","dateModified":"2026-08-26T04:57:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76673"},"wordCount":451,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76673#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2606.webp","keywords":["NYSE: TAK","Product approvals","Takeda","TYO: 4502"],"articleSection":["Company","Drug","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76673#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76673","url":"https:\/\/flcube.com\/?p=76673","name":"MHLW Approves Takeda's First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76673#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76673#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2606.webp","datePublished":"2026-08-26T04:56:59+00:00","dateModified":"2026-08-26T04:57:00+00:00","description":"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. The first\u2011in\u2011class oral orexin receptor 2 (OX2R) agonist is the only medicine indicated in Japan to treat the underlying cause of NT1, marking a paradigm shift from symptom management to disease\u2011targeted therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76673#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76673"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76673#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2606.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2606.webp","width":1080,"height":608,"caption":"MHLW Approves Takeda's First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76673#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MHLW Approves Takeda&#8217;s First\u2011in\u2011Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2606.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76673"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76673\/revisions"}],"predecessor-version":[{"id":76678,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76673\/revisions\/76678"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76677"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}